Palatin Technologies Earnings Call: Science vs. Cash
TipRanks (Tue, 29-Sep 8:05 PM ET)
Palatin Technologies GAAP EPS of -$1.11, revenue of $0.3M
Seeking Alpha News (Mon, 28-Sep 8:04 AM ET)
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
PRNewswire (Mon, 28-Sep 7:31 AM ET)
Here are the major earnings before the open Monday
Seeking Alpha News (Sun, 27-Sep 6:00 PM ET)
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Palatin Techs trades on the NASDAQ stock market under the symbol PTN.
As of September 30, 2026, PTN stock price declined to $9.07 with 19,653 million shares trading.
PTN has a beta of -1.48, meaning it tends to be less sensitive to market movements. PTN has a correlation of 0.02 to the broad based SPY ETF.
PTN has a market cap of $16.14 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that PTN belongs to (by Net Assets): VXF, IWC.
PTN support price is $8.27 and resistance is $9.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTN shares will trade within this expected range on the day.